Literature DB >> 34019961

E2F1 promotes proliferation and metastasis of clear cell renal cell carcinoma via activation of SREBP1-dependent fatty acid biosynthesis.

Donglai Shen1, Yu Gao2, Qingbo Huang3, Yundong Xuan4, Yuanxin Yao5, Liangyou Gu6, Yan Huang7, Yu Zhang8, Pin Li9, Yang Fan10, Lu Tang11, Songliang Du12, Shengpan Wu13, Hanfeng Wang14, Chenfeng Wang15, Huijie Gong16, Yuewen Pang17, Xin Ma18, Baojun Wang19, Xu Zhang20.   

Abstract

Enhanced synthesis or uptake of lipids contributes to rapid cancer cell proliferation and tumor progression. In recent years, cell cycle regulators have been shown to be involved in the control of lipid synthesis, in addition to their classical function of controlling the cell cycle. Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and is characterized by lipid-rich cytoplasmic deposition. However, the relationship between altered lipid metabolism and tumor progression in ccRCC is poorly understood. Here, we demonstrated that E2F transcription factor 1 (E2F1), in addition to its key role in regulating the cell cycle, induces extensive lipid accumulation and elevated levels of lipogenic enzymes in ccRCC cells by upregulating sterol regulatory element-binding protein 1 (SREBP1). E2F1 knockdown or SREBP1 suppression attenuated fatty acid (FA) de novo synthesis, cell proliferation and epithelial-mesenchymal transition (EMT) in ccRCC cells. Furthermore, overexpression of E2F1 promoted lipid storage, tumor growth and metastasis in a mouse xenograft model, whereas E2F1 downregulation or SREBP1 inhibition reversed these effects. In ccRCC patients, high levels of E2F1 and SREBP1 were associated with increased lipid accumulation and correlated with poor prognosis. Our results demonstrate that E2F1 can increase proliferation and metastasis through SREBP1-induced aberrant lipid metabolism, which is a novel critical signaling mechanism driving human ccRCC progression.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell cycle; Epithelial-mesenchymal transition; Lipid metabolism; Pharmacological inhibitor

Mesh:

Substances:

Year:  2021        PMID: 34019961     DOI: 10.1016/j.canlet.2021.05.012

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  KAT2A affects tumor metabolic reprogramming in colon cancer progression through epigenetic activation of E2F1.

Authors:  Xiaofeng Han; Jie Chen
Journal:  Hum Cell       Date:  2022-05-18       Impact factor: 4.174

2.  CircESRP1 enhances metastasis and epithelial-mesenchymal transition in endometrial cancer via the miR-874-3p/CPEB4 axis.

Authors:  Rui Shi; Wei Zhang; Jun Zhang; Zhicheng Yu; Lanfen An; Rong Zhao; Xing Zhou; Ziwei Wang; Sitian Wei; Hongbo Wang
Journal:  J Transl Med       Date:  2022-03-22       Impact factor: 5.531

Review 3.  Targeting SREBP-1-Mediated Lipogenesis as Potential Strategies for Cancer.

Authors:  Qiushi Zhao; Xingyu Lin; Guan Wang
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

4.  The SREBP-dependent regulation of cyclin D1 coordinates cell proliferation and lipid synthesis.

Authors:  Arwa Aldaalis; Maria T Bengoechea-Alonso; Johan Ericsson
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

5.  Cuproptosis-related gene FDX1 expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma.

Authors:  Tao Wang; Yufeng Liu; Qing Li; Yang Luo; Dawei Liu; Bin Li
Journal:  Front Immunol       Date:  2022-09-26       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.